Rising Concerns in the WHO European Region: The Growing Crisis of Liver Disease
Liver disease is emerging as a critical public health challenge in the WHO European Region, with non-alcoholic fatty liver disease (NAFLD) and related conditions driving alarming mortality and economic burdens. According to the World Health Organization (WHO), liver diseases account for approximately 780 deaths daily in the region, costing health systems an estimated €55 billion annually. Dr. Hans Henri P. Kluge, WHO Regional Director for Europe, emphasized that while other major causes of death, such as cardiovascular diseases and cancer, are declining, liver disease is escalating, underscoring an urgent need for action.
The Launch of the WHO’s First Liver Disease Cooperation Center
In response to this crisis, the WHO, in partnership with the Imperial College London and the European Association for the Study of the Liver (EASL), established the first WHO Cooperation Center dedicated to liver diseases. This initiative aims to translate scientific knowledge into actionable policies, leveraging EASL’s clinical and research networks to support national health strategies. The center will focus on preventing and managing conditions like NAFLD, which often progresses silently to cirrhosis and liver cancer.
Key Risk Factors and Prevention Opportunities
The primary drivers of liver disease in the region include excessive alcohol consumption, unhealthy diets, and viral hepatitis. A 2026 report by the EASL-Lancet Commission highlighted that addressing these modifiable risk factors could prevent nearly half of liver-related deaths. However, environmental factors—such as the widespread availability of ultra-processed foods and alcohol marketing—continue to exacerbate the problem. Public health experts warn that without systemic interventions, the burden of liver disease will persist.
Policy Measures and Global Frameworks
The 79th World Health Assembly in May 2026 marked a pivotal moment by officially recognizing NAFLD as a non-communicable disease (NCD) and urging member states to integrate prevention and treatment into national health plans. Key strategies include restricting the marketing of high-fat, high-sugar foods, taxing unhealthy products, and reducing alcohol availability. These measures align with the EASL-Lancet Commission’s recommendations to create healthier environments, particularly for vulnerable populations.
Challenges in Implementation and the Path Forward
Despite these efforts, translating policy into tangible outcomes remains challenging. Prof. Debbie Shawcross of EASL noted that while evidence for effective interventions exists, political will and resource allocation are critical. The new WHO Cooperation Center will play a central role in providing technical support, training, and tools to help countries implement these strategies. Over the next four years, the center will conduct regional assessments, develop evidence-based guidelines, and strengthen national liver disease programs.
Why This Matters: A Public Health Imperative
The rise of liver disease reflects broader failures in addressing lifestyle-related health risks. In the UK, NAFLD contributes to roughly 5% of hospital admissions, highlighting its strain on healthcare systems. Experts argue that tackling this issue requires coordinated action across sectors, from food regulation to public education. As Prof. Pinelopi Manousou of the WHO Cooperation Center stated, “For the first time, we have the infrastructure to drive lasting progress—but only if stakeholders act decisively.”
Looking Ahead: A Call for Systemic Change
The establishment of the WHO Liver Disease Cooperation Center represents a significant step toward combating a preventable public health crisis. However, success hinges on sustained investment, cross-sector collaboration, and a commitment to evidence-based policies. As global health leaders convene to address NCDs, the fight against liver disease serves as a critical test of their ability to turn research into real-world impact.
Related reading